Dr. Cavo on Upfront ASCT in Multiple Myeloma

Michele Cavo, MD
Published: Saturday, Jun 04, 2016



Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for the treatment of patients with multiple myeloma. 

In the study, patients were randomized to receive 4 cycles of bortezomib, melphalan, and prednisone versus high-dose melphalan and single or double ASCT as intensification therapy following induction with bortezomib, cyclophosphamide, and dexamethasone and subsequent collection of peripheral blood stem cells.  

The difference between the 2 arms was statistically significant, Cavo explains. Additionally, there was an improvement in progression-free survival with ASCT. Results show that ASCT remains to be a preferred treatment regimen in newly diagnosed patients with multiple myeloma, he adds.
 

<<< View more from the 2016 ASCO Annual Meeting



Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for the treatment of patients with multiple myeloma. 

In the study, patients were randomized to receive 4 cycles of bortezomib, melphalan, and prednisone versus high-dose melphalan and single or double ASCT as intensification therapy following induction with bortezomib, cyclophosphamide, and dexamethasone and subsequent collection of peripheral blood stem cells.  

The difference between the 2 arms was statistically significant, Cavo explains. Additionally, there was an improvement in progression-free survival with ASCT. Results show that ASCT remains to be a preferred treatment regimen in newly diagnosed patients with multiple myeloma, he adds.
 

<<< View more from the 2016 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x